John Hubbard, MD
Psychiatry · Tuscaloosa, ALNPI 1881640555
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 713 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,654, 7.9 times the $587 reported in 2019. Among psychiatry clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 713 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Vanda Pharmaceuticals Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Neurocrine Biosciences, Inc.$875
- plus $6K from 21 others
What the payments were for
- Food & beverage$14,48699%
- Education$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 123 | $2,486 |
| AbbVie(2 entities) | 118 | $2,248 |
| Teva Pharmaceuticals USA, Inc. | 70 | $1,212 |
| Vanda Pharmaceuticals Inc. | 38 | $1,134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 56 | $1,033 |
| Neurocrine Biosciences, Inc. | 43 | $875 |
| Otsuka America Pharmaceutical, Inc. | 38 | $819 |
| Alkermes, Inc. | 36 | $739 |
| Johnson & Johnson | 27 | $700 |
| E.r. Squibb & Sons, L.L.C. | 18 | $659 |
| Bausch Health US, LLC | 24 | $494 |
| Lundbeck LLC | 22 | $456 |
| Axsome Therapeutics, Inc. | 13 | $350 |
| Tris Pharma Inc | 23 | $299 |
| Corium, LLC | 12 | $290 |
| Sunovion Pharmaceuticals Inc. | 11 | $130 |
| Shire North American Group Inc | 9 | $129 |
| Neos Therapeutics, LP | 6 | $102 |
| Supernus Pharmaceuticals, Inc. | 6 | $98 |
| Adlon Therapeutics L.p. | 6 | $87 |
| Idorsia Pharmaceuticals US Inc | 5 | $83 |
| Ironshore Pharmaceuticals Inc. | 3 | $56 |
| Merck | 2 | $31 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Vertical Pharmaceuticals, LLC | 1 | $16 |
| Indivior Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$728
- CAPLYTA$620
- Austedo XR$368
- Fanapt$248
- COBENFY$242
- INGREZZA$125
- ABILIFY MAINTENA$122
- ABILIFY ASIMTUFII$122
- UZEDY$121
- Auvelity$121
How this compares
$14,571 in reported general payments places this provider in the 90th percentile of 400 psychiatry providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 11 | $107,678 |
| IngrezzaValbenazine Tosylate | 15 | $103,525 |
| VraylarCariprazine Hcl | 69 | $94,643 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $18,510 |
| Lurasidone Hcl | 24 | $6,938 |
| Bupropion XlBupropion Hcl | 183 | $3,019 |
| Clozapine | 11 | $2,974 |
| Aripiprazole | 64 | $2,956 |
| Atomoxetine Hcl | 28 | $2,830 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 43 | $2,435 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 46 | $1,929 |
| Buspirone Hcl | 108 | $1,866 |
| Clonazepam | 231 | $1,485 |
| Hydroxyzine Hcl | 186 | $1,375 |
| Divalproex Sodium | 12 | $1,287 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,212 | $107,67811 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $875 | $103,52515 claims |
| AbbVieVraylar | $2,248 | $94,64369 claims |
| Alkermes, Inc.Lybalvi | $739 | $18,51013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 400 psychiatry providers in Alabama.
Other psychiatry in Tuscaloosa
- Lori DavisTuscaloosa$161K
- Aftab KhanTuscaloosa$10K
- Armand SchachterBirmingham$758K
- Stephen HughesBirmingham$683K
- Leesha Ellis CoxBirmingham$653K
- Godehard OepenBirmingham$516K
- Scariya KumaramangalamHuntsville$440K
- Mark HaygoodMobile$348K
- Bradley SadlerMobile$124K
- Brandi Rudolph BollingJasper$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.